Experience with Sonidegib in Patients with Advanced Basal Cell Carcinoma: Case Reports

Sonidegib, a Hedgehog signaling pathway inhibitor, was used to treat three patients with advanced basal cell carcinoma (BCC), including two with locally advanced BCC and one with Gorlin syndrome. The treatment led to remission in the locally advanced BCC cases within 7 months and reduced lesion size and number in the Gorlin syndrome case after 4 months. Adverse effects such as cramps, alopecia, ageusia, and weight loss were mild and consistent with sonidegib's known toxicity profile. The study highlights sonidegib's effectiveness in challenging BCC cases and emphasizes the need for improved management protocols, including earlier intervention and a multidisciplinary approach.